Clinical Trial Update: Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tacrolimus ointment at 0.1% and 0.03% for adults with moderate to severe atopic dermatitis has completed, assessing its efficacy and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tacrolimus ointment 0.1% and 0.03% (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED